Prognostic Methylation Markers for Survival in Cytogenetically Normal AML Patients Treated on SWOG Trials

被引:0
|
作者
Qu, Xiaoyu [1 ,2 ]
Othus, Megan [1 ,3 ]
Davison, Jerry [1 ]
Yan, Liying [4 ]
Estey, Elihu H. [2 ,5 ,6 ]
Radich, Jerry [1 ,2 ,3 ,7 ]
Erba, Harry P. [3 ,8 ]
Appelbaum, Frederick R. [1 ,2 ,3 ,7 ]
Fang, Min [1 ,2 ,3 ,7 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[2] Seattle Canc Care Alliance, Seattle, WA USA
[3] SWOG Leukemia Comm, Portland, OR USA
[4] EpigenDx Inc, Boston, MA USA
[5] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[6] Univ Washington, Div Hematol, Seattle, WA 98195 USA
[7] Univ Washington, Seattle, WA 98195 USA
[8] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页数:3
相关论文
共 50 条
  • [1] Prognostic Methylation Markers for Overall Survival in Cytogenetically Normal Patients With Acute Myeloid Leukemia Treated on SWOG Trials
    Qu, Xiaoyu
    Othus, Megan
    Davison, Jerry
    Wu, Yu
    Yan, Liying
    Meshinchi, Soheil
    Ostronoff, Fabiana
    Estey, Elihu H.
    Radich, Jerry P.
    Erba, Harry P.
    Appelbaum, Frederick R.
    Fang, Min
    CANCER, 2017, 123 (13) : 2472 - 2481
  • [2] DNA Methylation as a Prognostic Marker of Survival In Patients With Cytogenetically Normal Acute Myeloid Leukemia
    Qu, X.
    Davison, J.
    Othus, M.
    Du, L.
    Appelbaum, F.
    Estey, E.
    Fang, M.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2012, 14 (06): : 653 - 653
  • [3] A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)
    Pastore, Friederike
    Dufour, Annika
    Benthaus, Tobias
    Metzeler, Klaus H.
    Maharry, Kati
    Schneider, Stephanie
    Ksienzyk, Bianka
    Mellert, Gudrun
    Zellmeier, Evelyn
    Kakadia, Purvi M.
    Unterhalt, Michael
    Feuring-Buske, Michaela
    Buske, Christian
    Braess, Jan
    Sauerland, Cristina
    Heinecke, Achim
    Krug, Utz
    Berdel, Wolfgang E.
    Buechner, Thomas
    Woermann, Bernhard J.
    Hiddemann, Wolfgang
    Bohlander, Stefan K.
    Marcucci, Guido
    Spiekermann, Karsten
    Bloomfield, Clara D.
    Hoster, Eva
    BLOOD, 2013, 122 (21)
  • [4] PROGNOSTIC RELEVANCE OF MN1 EXPRESSION IN CYTOGENETICALLY NORMAL ADULT AML PATIENTS
    Chopra, Anita
    Ningombam, Aparna
    Verma, Deepak
    Kumar, Rajive
    Singh, Jay
    Ali, M. Shadab
    Pandey, Avnish
    Singh, Inder
    Bakhshi, Sameer
    Sharma, Atul
    Pushpam, Deepam
    Palanichamy, Jayanth
    Tanwar, Pranay
    Singh, Amar
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2023, 45 : 44 - 44
  • [5] Nm23 as a new prognostic marker for cytogenetically normal AML
    Mueller, E.
    Niederwieser, D.
    Cross, M.
    EXPERIMENTAL HEMATOLOGY, 2007, 35 (09) : 65 - 65
  • [6] Mutations in patients with cytogenetically normal AML predict treatment outcome
    Nature Clinical Practice Oncology, 2008, 5 (8): : 433 - 433
  • [7] K-RAS MUTATIONS IN CYTOGENETICALLY NORMAL AML PATIENTS
    Morgan, A.
    Krauter, J.
    Onono, F.
    Bunke, T.
    Damm, F.
    Goehring, G.
    Schegelberger, B.
    Ganser, A.
    Reuter, C. W. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 26 - 26
  • [8] Immunophenotypic identities of clinical samples have the potential to correlate with overall survival in cytogenetically normal AML patients
    Gaj, Pawel
    Nowis, Dominika
    Volinia, Stefano
    CANCER RESEARCH, 2016, 76
  • [9] The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML
    S M Sun
    V Rockova
    L Bullinger
    M K Dijkstra
    H Döhner
    B Löwenberg
    M Jongen-Lavrencic
    Leukemia, 2013, 27 : 100 - 106
  • [10] The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML
    Sun, S. M.
    Rockova, V.
    Bullinger, L.
    Dijkstra, M. K.
    Doehner, H.
    Lowenberg, B.
    Jongen-Lavrencic, M.
    LEUKEMIA, 2013, 27 (01) : 100 - 106